Stockscreener 앱 받기
2.23
5.69%
0.12
시장 영업 전:
2.13
-0.10
-4.48%
전일 마감가:
$2.11
열려 있는:
$2.11
하루 거래량:
1.07M
Relative Volume:
1.20
시가총액:
$350.18M
수익:
$79,600
순이익/손실:
$-48.26M
주가수익비율:
-4.5307
EPS:
-0.4922
순현금흐름:
$-28.24M
1주 성능:
+13.78%
1개월 성능:
+21.86%
6개월 성능:
+35.15%
1년 성능:
+21.20%
1일 변동 폭
$2.10
$2.26
1주일 범위
$1.93
$2.36
52주 변동 폭
$1.33
$2.36
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
2.23 | 350.18M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-04 | 개시 | Ladenburg Thalmann | Buy |
| 2026-01-21 | 개시 | BofA Securities | Buy |
| 2025-12-26 | 개시 | H.C. Wainwright | Buy |
| 2025-12-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Frontier tech research, news & data - MLQ.ai
RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics - Bitget
Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT) - Stock Titan
RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase - Stock Titan
IKT Receives FDA Orphan Designation for Pulmonary Arterial Hyper - GuruFocus
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - Sahm
Inhibikase raises $50M to fund PAH program - TipRanks
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Brokerages - MarketBeat
Inhibikase Therapeutics Shares Rise on $50M At‐the‐Market Share Sale - Moomoo
Inhibikase raises $50 million through stock sale to RA Capital - Investing.com
Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility - TradingView
Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH - MarketBeat
Inhibikase raises $50 million through stock sale to RA Capital By Investing.com - Investing.com Canada
Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash - Stock Titan
Inhibikase's $50M share sale could support Phase 3 PAH readout - Stock Titan
Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9%Here's What Happened - MarketBeat
Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn ContinuesAnnual Earnings Summary - dars.gov.et
Inhibikase Therapeutics Inc. (IKT) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et
INHIBIKASE THERAPEUTICS INC (IKT) Stock Chart - ChartMill
Inhibikase Therapeutics Inc (NASDAQ: IKT) Share Price, IKT Stock News, IKT Share Price & Updates - Kalkine
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Inhibikase awards stock options to 7 new hires under inducement plan - Stock Titan
Director at Inhibikase (NASDAQ: IKT) receives 155K stock options grant - Stock Titan
Inhibikase (IKT) director awarded 155,000 stock options at $1.91 exercise price - Stock Titan
Inhibikase (NASDAQ: IKT) investors back 3M-share plan boost and officer protections - Stock Titan
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to sales forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Enterprise value to EBIT forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to sales forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to earnings forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to book forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to book forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to earnings forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Inhibikase Therapeutics, Inc. Actuals & Estimates (NASDAQ:IKT) - TradingView
IKT Forecast — Price Target — Prediction for 2027 - TradingView
Inhibikase Therapeutics Inc (IKT) Institutional Confidence - TradingKey
Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Inhibikase Therapeutics Inc (IKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inhibikase Therapeutics (IKT) Holds Steady Near Support as Traders Await CatalystDividend Stock Picks - DonanımHaber
Inhibikase Therapeutics Inc (IKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Inhibikase Therapeutics Inc (IKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inhibikase Therapeutics Inc (IKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibikase Therapeutics Inc (IKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
3.77%
자본화:
|
볼륨(24시간):